Our People

Sébastien Jacquelin

Dr | Research Officer

Functional Cancer Genomics

+61 7 3845 3070




Sebastien Jacquelin is a researcher with special interest in Stem cell, Cancer, Epigenetic, DNA topology and Tumour Immunology. He received his PHD from the University of Paris Sud XI in 2013 in cancer immunology and Life Science in 2013. He performed a post doc in the field of leukaemia in QIMR Berghofer in Brisbane and acquired expertise in geno-editing epigenetic and cancer biology. In 2019, he joined the Functional Cancer Genomics laboratory. His work aim to understand how genetic variants alter non-coding genome dynamic, chromatin topology and contributes to breast cancer development.



2019–current: Research Officer-Functional Cancer Genomics Laboratory



2014-2019: Gordon and Jessie Gilmour Leukaemia Laboratory QIMR Berghofer Brisbane Australia

2010-2013: PhD, INSERM, Pitié-Salpêtrière hospital Paris, France

2009-2010: Research engineer, INSERM, St Antoine hospital Paris, France

2006-2009: Research engineer, INSERM, Necker hospital Paris, France

2003-2006: Sales engineer, ADS Laminaire, Le Pre St Gervais, France

2003: Research assistant INSERM, Bichat hospital

2002: Research assistant, CEA, (Atomic Energy Commissariat), Cadarache, France

2001-2002: Research assistant, Pasteur Institute, Paris, France

2000-2001: Research assistant, CEA, St Louis hospital Paris, France

1997-1999: Research assistant, IRSN (Radioprotection and nuclear Safety Institute), FAR, France






The Functional Cancer Genomics Laboratory focuses on understanding how DNA variation contributes to cancer risk and development. The laboratory is particularly interested in translating the findings from cancer genome-wide association studies (GWAS). Our research aims to understand how DNA sequence variation effects local topology and causes changes in gene expression that promotes cancer transformation. Using RNA CaptureSeq we identified >4000 Long noncoding RNAs (LncRNAs) transcribed from cancer risk regions that were not previously annotated. The expression of LncRNAS is cell type specific and define biological signature allowing precise identification of cell subtype. Importantly, LncRNAs expression pattern discriminate normal cells from cancer cells. My research aim to understand the role of these newly identified LncRNAs in normal and cancer cell development. To perform my research I have developed a CRISPR Cas13d screening platform to target the non-coding genome and assess its function in primary cells and cancer cells development.



Sebastien Jacquelin’s research career have been mainly devoted to the field of cancer, immunology and epigenetic with specific focus in leukaemia and Breast cancer.

  • 2018-Publication-(Blood-IF; 16.6). Geno editing on primary cell targeting epigenetic enzyme (Dnmt3A) accelerate myeloid malignancy (myelofibrosis) transformation- Jacquelin et al
  • 2018- Publication-(J Clin Invest-IF; 11.8). CRISPR-Cas9 targeting of immune suppressive molecule CD155 enhances tumor suppression via combined host and tumor-intrinsic mechanisms. Li et al
  • 2016- Publication-(Blood -IF16.6). Role of chemokine receptor (CX3CR1) on monocyte motility after chemotherapy. Jacquelin et al



  • 2017–2018: International Society of Experimental Haematology  member



  • 2016: Best of oral presentation from American Society of Haematology conference, San Diego



  • 2013: PhD, Life Science-Immunology Paris Sud XI University
  • 2009: Engineering degree, Life Science
  • 2001: Bachelor’s degree, Industrial Bioexperimentation
  • 2000: AVTC, Biochemistry